Compare · STE vs XPEL
STE vs XPEL
Side-by-side comparison of STERIS plc (Ireland) (STE) and XPEL Inc. (XPEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- STE operates in Health Care, while XPEL operates in Industrials - the two are in different parts of the market.
- STE is the larger of the two at $20.50B, about 16.6x XPEL ($1.24B).
- Over the past year, STE is down 13.5% and XPEL is up 19.5% - XPEL leads by 33.0 points.
- STE has been more active in the news (39 items in the past 4 weeks vs 2 for XPEL).
- STE has more recent analyst coverage (16 ratings vs 3 for XPEL).
- Company
- STERIS plc (Ireland)
- XPEL Inc.
- Price
- $210.04-1.01%
- $44.98+1.12%
- Market cap
- $20.50B
- $1.24B
- 1M return
- -1.87%
- +2.34%
- 1Y return
- -13.48%
- +19.53%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 39
- 2
- Recent ratings
- 16
- 3
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
XPEL Inc.
XPEL, Inc. manufactures, sells, distributes, and installs after-market automotive products in the United States, China, Canada, Continental Europe, the United Kingdom, Asia Pacific, Latin America, the Middle East/Africa, and internationally. The company offers automotive surface and paint protection, headlight protection, and automotive and architectural window films, as well as proprietary software. It also provides merchandise and apparel, and ceramic coatings. In addition, the company offers paint protection kits, car wash products, after-care products, and installation tools through its website. It sells its products to independent installers and new car dealerships, third party distributors, owned installation centers, and franchisees and online. The company was founded in 1997 and is headquartered in San Antonio, Texas.
Latest STE
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 401 units of Ordinary Shares, decreasing direct ownership by 1% to 36,678 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 65 units of Ordinary Shares, decreasing direct ownership by 1% to 6,194 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 195 units of Ordinary Shares, decreasing direct ownership by 2% to 12,257 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 150 units of Ordinary Shares, decreasing direct ownership by 1% to 11,332 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 600 units of Ordinary Shares, decreasing direct ownership by 4% to 13,716 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 1,889 units of Ordinary Shares and sold $946,799 worth of Ordinary Shares (4,428 units at $213.82), decreasing direct ownership by 9% to 63,647 units (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L covered exercise/tax liability with 90 units of Ordinary Shares, decreasing direct ownership by 0.68% to 13,184 units (SEC Form 4)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 365 units of Ordinary Shares, decreasing direct ownership by 0.97% to 37,079 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 64 units of Ordinary Shares, decreasing direct ownership by 1% to 6,259 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 239 units of Ordinary Shares, decreasing direct ownership by 2% to 12,452 units (SEC Form 4)
Latest XPEL
- XPEL Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
- XPEL Announces Approximately $110 Million Manufacturing and Supply Chain Investment, Including Expansion of San Antonio Operations and Acquisition of Manufacturing Facility in China
- Amendment: SEC Form SCHEDULE 13G/A filed by XPEL Inc.
- XPEL Marks Skin Cancer Awareness Month and National Don't Fry Day with Limited-Time Window Tint Offer to Help Drivers Beat Heat and UV Exposure
- SEC Form 10-Q filed by XPEL Inc.
- XPEL Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- XPEL Reports Revenue Growth of 13.1% to $117.4 million, EBITDA Growth of 17.8% to $17.0 million in First Quarter 2026
- SEC Form 3 filed by new insider Thornton Mark Andrew
- SEC Form DEFA14A filed by XPEL Inc.
- SEC Form DEF 14A filed by XPEL Inc.